2880-LB: Safety and Efficacy of Rapid-Acting Concentrated U200 Insulin in Automatic Insulin Delivery System (AID) Minimed 780G: Retrospective Real Live Study

Introduction and Objective: Severe insulin resistance makes automatization of insulin delivery difficult for some people with DM. U200 insulin is used to overcome this. To evaluate the safety and efficacy of U200 Insulin in minimed 780G AID we retrospectively analyzed the data of 1104 AID users at the DGD Clinic in San Antonio TX. Methods: Data of 17 patients was found. 12 female, avg age 53 yr, avg duration DM 24.5 yr. Downloads of the patients 780G AID were examined at 3 month intervals for 1 year starting when the AID and U200 insulin began to be used concomitantly. Data was compared with previous downloads found for each patient in our EMR (One way ANOVA RM) Results: Among users of 780G AID with U200 insulin, Hgb A1C decreased and time in range increased significantly. Non-significant change in time below range or weight were observed. Subgroup analysis showed that T2DM patients had significantly more time in range. Patients who migrated from other AID systems to the 780G with U200 insulin, had significantly less time below range. Many improved tendencies, close to statistical significance, were observed. We hope that a subsequent analysis with a longer duration and larger number of patients will make these observations more evident. Conclusion: The use of U200 insulin in people using minimed 780G AID showed significant improvement in glycemic control and time in range without significant increase of time below range or weight Disclosure W. Trigoso: Speaker's Bureau; Current; Lilly, Boehringer Ingelheim International GmbH. T.M. Copple: Speaker's Bureau; Current; Kyowa Kirin Co., Ltd.